(OCR) Spark Programme @Ipsen

Ipsen is a leading global biopharmaceutical company dedicated to improving lives through innovative medicines in Oncology, Rare Disease, and Neuroscience. We are seeking motivated graduate degree candidates for our accelerated growth program, Spark! Spark is a 3 to 5-year global accelerated program that offers extensive training, coaching, and visibility to senior management. The program is structured as several 12-month rotations, each in a different function within the company. These include rotations in areas such as but not limited to Sales, Marketing, Operations, Market Access, Business Development, and Digital Health. After the rotations, Sparks will be placed into a supervisory role for 2 to 3 years before ultimately growing into a succession plan for global pivotal role (General Manager, Medical Director, R&D Asset Lead, Business Unit Head, Global Brand Lead, etc.). The program includes participation to an active Spark community, Global Leadership Team mentorship, an individual coaching journey, and eligibility to multi-job assignments including international. As Spark is a performance-based program, these all depend on individual performance. This program is an excellent opportunity for individuals to gain broad and meaningful work experiences that will prepare them for a successful career to become future leaders within Ipsen and beyond. Successful Spark candidates will have strong leadership potential, a passion for improving lives through innovative medicines and an educational or experience background in science and business.

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Neuroscience is advancing at an unprecedented rate and Ipsen is at the forefront of this transformation. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €2.5 billion in 2020, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide.